Ever Supreme Bio Technology Co., Ltd. 6712

TPEX · Taiwan · Health Technology

TWD 161.00-1.00 (-0.62%)

Market open· Oct 2, 2026, 2:57 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Ever Supreme Bio Technology Co., Ltd. 6712

TPEX · Taiwan · Health Technology

TWD 161.00-1.00 (-0.62%)

Market open· Oct 2, 2026, 2:57 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+20.32% · 6MFull-screen chart

Open TWD 165.00High TWD 167.00Low TWD 160.50Close TWD 161.00Volume 297.00K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: TWD 162.00
Day range: TWD 160.50 – TWD 167.00
52-week range: TWD 120.95 – TWD 184.00
Volume: 297.00K
Market cap: TWD 16.28B
P/E (TTM): 32.7
Dividend yield (annualized): 2.06%
Next earnings date: 2026-11-17
Avg. volume (1Y): 379.63K

Performance

1 week

-0.31%

1 month

+2.22%

3 months

-0.31%

6 months

+22.46%

Year to date

+3.14%

1 year

-7.34%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Taiwan
Exchange: TPEX
Shares outstanding: 99.45M
ISIN: TW0006712003
Beta: 0.27

Technical view

Above averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJun 29, 2026

Ever Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansion

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR-T cell therapy for cancer, has successfully cleared review by the Safety Monitoring Committee (SMC). Following a thorough evaluation of the Phase I safety profile and preliminary efficacy data, the committee has greenlit the advancement to the Phase IIa clinical trial. This milestone marks the successful completion of the critical safety assessment dur

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.